Minyi J. Cai

Zhejiang Province Key Laboratory Of Anti Cancer Drug Research
Hangzhou, 310058, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

P2RY8::TSC22D3 is a novel fusion associated with chemoresistance in leukemia by activating PI3K-AKT pathway.

P2RY8::TSC22D3 is a novel fusion associated with chemoresistance in leukemia by activating PI3K-AKT pathway.

Journal: Cancer letters

Published: May 29, 2025

Chromosomal rearrangement-enhanced mRNA stability drives the oncogenic potential of fusion genes in pediatric leukemia.

Chromosomal rearrangement-enhanced mRNA stability drives the oncogenic potential of fusion genes in pediatric leukemia.

Journal: Haematologica

Published: May 19, 2025

Metabolomics and metabolites in cancer diagnosis and treatment.

Metabolomics and metabolites in cancer diagnosis and treatment.

Journal: Molecular biomedicine

Published: January 07, 2025

Phase separation-based screening identifies arsenic trioxide as the N-Myc-DNA interaction inhibitor for neuroblastoma therapy.

Phase separation-based screening identifies arsenic trioxide as the N-Myc-DNA interaction inhibitor for neuroblastoma therapy.

Journal: Cancer letters

Published: October 28, 2024

Report of six cases with mast cell leukemia and a literature review

Report of six cases with mast cell leukemia and a literature review

Journal: Zhonghua nei ke za zhi

Published: October 07, 2024

The palmitoyltransferase ZDHHC21 regulates oxidative phosphorylation to induce differentiation block and stemness in AML.

The palmitoyltransferase ZDHHC21 regulates oxidative phosphorylation to induce differentiation block and stemness in AML.

Journal: Blood

Published: November 15, 2022

Deneddylation of PML/RARα reconstructs functional PML nuclear bodies via orchestrating phase separation to eradicate APL.

Deneddylation of PML/RARα reconstructs functional PML nuclear bodies via orchestrating phase separation to eradicate APL.

Journal: Cell death and differentiation

Published: October 06, 2021

Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells.

Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells.

Journal: Acta pharmaceutica Sinica. B

Published: July 20, 2021

Protein phase separation: A novel therapy for cancer?

Protein phase separation: A novel therapy for cancer?

Journal: British journal of pharmacology

Published: May 24, 2020

Showing 1-9 of 9

Last Updated: 09/26/2026